Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$73.08
+2.8%
$76.59
$55.02
$98.40
$3.46B1.13729,318 shs703,039 shs
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
$14.67
+0.6%
$15.66
$9.90
$17.73
$1.19B0.39524,605 shs426,396 shs
FibroGen, Inc. stock logo
FGEN
FibroGen
$1.07
-6.1%
$1.87
$0.33
$20.28
$105.68M0.72.47 million shs1.35 million shs
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$10.71
-1.0%
$12.08
$9.70
$14.57
$3.20B0.753.04 million shs5.09 million shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$25.41
-2.2%
$28.10
$17.53
$59.84
$1.95B0.67967,511 shs754,373 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+2.78%+6.21%-9.40%-20.37%-0.33%
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
+0.62%-1.15%-3.68%+3.82%+2.44%
FibroGen, Inc. stock logo
FGEN
FibroGen
-6.14%-17.69%-58.53%+10.28%-93.66%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
-1.02%+1.42%-7.11%-14.80%-6.79%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-2.16%+0.47%-12.65%-6.62%-51.92%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
4.4579 of 5 stars
4.50.00.04.52.14.20.6
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
3.4238 of 5 stars
3.40.00.03.82.71.70.6
FibroGen, Inc. stock logo
FGEN
FibroGen
4.4231 of 5 stars
2.94.00.04.73.33.30.6
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
3.8931 of 5 stars
3.50.00.04.32.70.81.9
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
3.4815 of 5 stars
2.92.00.04.42.70.80.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.92
Moderate Buy$119.6763.75% Upside
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
2.80
Moderate Buy$23.0056.78% Upside
FibroGen, Inc. stock logo
FGEN
FibroGen
1.75
Reduce$17.001,488.79% Upside
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
3.00
Buy$20.0086.74% Upside
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
1.85
Reduce$33.5331.97% Upside

Current Analyst Ratings

Latest FOLD, PTCT, FGEN, DCPH, and AXSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/12/2024
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/10/2024
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$107.00
4/2/2024
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$190.00
3/28/2024
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$108.00 ➝ $109.00
3/26/2024
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$150.00
3/26/2024
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$180.00 ➝ $190.00
3/26/2024
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$125.00 ➝ $127.00
3/26/2024
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$123.00 ➝ $128.00
3/20/2024
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$180.00
3/20/2024
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$14.00 ➝ $16.00
3/20/2024
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$33.00 ➝ $35.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$270.60M12.79N/AN/A$4.04 per share18.09
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
$163.36M7.26N/AN/A$4.38 per share3.35
FibroGen, Inc. stock logo
FGEN
FibroGen
$147.75M0.72N/AN/A($1.87) per share-0.57
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$399.36M7.92N/AN/A$0.55 per share19.47
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$937.82M2.08$2.43 per share10.45($10.85) per share-2.34

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$239.24M-$5.20N/A137.89N/A-88.41%-70.67%-27.47%5/6/2024 (Confirmed)
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
-$194.94M-$2.29N/AN/AN/A-119.33%-49.44%-38.41%5/1/2024 (Estimated)
FibroGen, Inc. stock logo
FGEN
FibroGen
-$284.23M-$2.93N/AN/AN/A-192.37%N/A-51.00%5/13/2024 (Estimated)
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
-$151.58M-$0.51N/A31.50N/A-37.96%-119.46%-20.40%5/8/2024 (Estimated)
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-$626.60M-$8.36N/AN/AN/A-66.82%N/A-32.06%4/25/2024 (Confirmed)

Latest FOLD, PTCT, FGEN, DCPH, and AXSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2024N/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$1.22N/A+$1.22N/AN/AN/A  
4/25/2024N/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-$1.31N/A+$1.31N/AN/AN/A  
2/29/2024Q4 2023
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$0.29-$0.24-$0.53$1.58$315.90 million$307.06 million
2/28/2024Q4 2023
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
-$0.06-$0.11-$0.05-$0.11$115.11 million$115.08 million
2/26/2024Q4 2023
FibroGen, Inc. stock logo
FGEN
FibroGen
-$0.42-$0.57-$0.15-$0.57$40.00 million$27.14 million
2/20/2024Q4 2023
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$1.21-$0.73+$0.48$0.62$70.38 million$71.53 million
2/6/2024Q4 2023
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
-$0.58-$0.54+$0.04-$0.54$45.93 million$48.30 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
N/AN/AN/AN/AN/A
FibroGen, Inc. stock logo
FGEN
FibroGen
N/AN/AN/AN/AN/A
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
N/AN/AN/AN/AN/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
0.93
3.63
3.52
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
N/A
3.80
3.59
FibroGen, Inc. stock logo
FGEN
FibroGen
N/A
1.52
1.33
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
2.42
2.88
2.52
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
2.02
1.97

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
70.96%
FibroGen, Inc. stock logo
FGEN
FibroGen
72.71%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
N/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
54547.37 million35.77 millionOptionable
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
35580.80 million77.22 millionOptionable
FibroGen, Inc. stock logo
FGEN
FibroGen
48698.77 million96.41 millionOptionable
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
517295.38 million289.18 millionOptionable
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
98876.61 million72.55 millionOptionable

FOLD, PTCT, FGEN, DCPH, and AXSM Headlines

SourceHeadline
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com - April 23 at 4:30 PM
Insider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells 3,361 Shares of StockInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells 3,361 Shares of Stock
insidertrades.com - April 23 at 5:08 AM
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Reduce" from BrokeragesPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Reduce" from Brokerages
americanbankingnews.com - April 23 at 4:26 AM
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of "Reduce" by BrokeragesPTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of "Reduce" by Brokerages
marketbeat.com - April 23 at 4:26 AM
Matthew B. Klein Sells 3,361 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) StockMatthew B. Klein Sells 3,361 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock
marketbeat.com - April 22 at 6:58 PM
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Knights of Columbus Asset Advisors LLCPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Knights of Columbus Asset Advisors LLC
marketbeat.com - April 21 at 6:39 AM
Eric Pauwels Sells 787 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) StockEric Pauwels Sells 787 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock
americanbankingnews.com - April 21 at 5:50 AM
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Down to $24.69PTC Therapeutics (NASDAQ:PTCT) Shares Gap Down to $24.69
americanbankingnews.com - April 21 at 3:08 AM
PTC Therapeutics CEO sells shares worth over $19kPTC Therapeutics CEO sells shares worth over $19k
investing.com - April 21 at 12:52 AM
Insider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells 787 Shares of StockInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells 787 Shares of Stock
insidertrades.com - April 20 at 7:28 AM
PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Eric Pauwels Sells 787 SharesPTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Eric Pauwels Sells 787 Shares
marketbeat.com - April 19 at 6:45 PM
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
zacks.com - April 18 at 11:06 AM
PTC Therapeutics (PTCT) Set to Announce Quarterly Earnings on ThursdayPTC Therapeutics (PTCT) Set to Announce Quarterly Earnings on Thursday
americanbankingnews.com - April 18 at 2:48 AM
PTC Therapeutics (NASDAQ:PTCT) Stock Rating Reaffirmed by Cantor FitzgeraldPTC Therapeutics (NASDAQ:PTCT) Stock Rating Reaffirmed by Cantor Fitzgerald
americanbankingnews.com - April 14 at 1:26 AM
PTC Therapeutics to Host Conference Call to Discuss  First Quarter 2024 Financial ResultsPTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
finance.yahoo.com - April 11 at 10:17 AM
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial ResultsPTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
prnewswire.com - April 11 at 8:00 AM
PTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Sells $14,922.62 in StockPTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Sells $14,922.62 in Stock
insidertrades.com - April 5 at 7:46 AM
Solid Biosciences gets FDA rare pediatric disease status for DMD therapySolid Biosciences gets FDA rare pediatric disease status for DMD therapy
msn.com - April 1 at 10:30 AM
Vanguard Group Inc. Boosts Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT)Vanguard Group Inc. Boosts Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT)
marketbeat.com - April 1 at 4:12 AM
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Bought by Assenagon Asset Management S.A.PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Bought by Assenagon Asset Management S.A.
marketbeat.com - March 31 at 4:42 AM
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMAPTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
finance.yahoo.com - March 28 at 9:46 AM
PTC Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- PTCTPTC Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- PTCT
accesswire.com - March 26 at 7:20 AM
PTC Therapeutics, Inc. (PTCT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky InvestigatesPTC Therapeutics, Inc. (PTCT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
accesswire.com - March 25 at 7:30 AM
PTCT ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your PTC Therapeutics, Inc. investmentPTCT ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your PTC Therapeutics, Inc. investment
accesswire.com - March 22 at 7:20 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Axsome Therapeutics logo

Axsome Therapeutics

NASDAQ:AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Deciphera Pharmaceuticals logo

Deciphera Pharmaceuticals

NASDAQ:DCPH
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
FibroGen logo

FibroGen

NASDAQ:FGEN
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Amicus Therapeutics logo

Amicus Therapeutics

NASDAQ:FOLD
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
PTC Therapeutics logo

PTC Therapeutics

NASDAQ:PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.